162 related articles for article (PubMed ID: 27491708)
61. Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical candidate 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the treatment of schizophrenia.
Verhoest PR; Chapin DS; Corman M; Fonseca K; Harms JF; Hou X; Marr ES; Menniti FS; Nelson F; O'Connor R; Pandit J; Proulx-Lafrance C; Schmidt AW; Schmidt CJ; Suiciak JA; Liras S
J Med Chem; 2009 Aug; 52(16):5188-96. PubMed ID: 19630403
[TBL] [Abstract][Full Text] [Related]
62. Discovery and optimization of potent and selective imidazopyridine and imidazopyridazine mTOR inhibitors.
Peterson EA; Boezio AA; Andrews PS; Boezio CM; Bush TL; Cheng AC; Choquette D; Coats JR; Colletti AE; Copeland KW; DuPont M; Graceffa R; Grubinska B; Kim JL; Lewis RT; Liu J; Mullady EL; Potashman MH; Romero K; Shaffer PL; Stanton MK; Stellwagen JC; Teffera Y; Yi S; Cai T; La DS
Bioorg Med Chem Lett; 2012 Aug; 22(15):4967-74. PubMed ID: 22765895
[TBL] [Abstract][Full Text] [Related]
63. Design, synthesis, and biological evaluation of 8-biarylquinolines: a novel class of PDE4 inhibitors.
Gallant M; Chauret N; Claveau D; Day S; Deschênes D; Dubé D; Huang Z; Lacombe P; Laliberté F; Lévesque JF; Liu S; Macdonald D; Mancini J; Masson P; Mastracchio A; Nicholson D; Nicoll-Griffith DA; Perrier H; Salem M; Styhler A; Young RN; Girard Y
Bioorg Med Chem Lett; 2008 Feb; 18(4):1407-12. PubMed ID: 18207397
[TBL] [Abstract][Full Text] [Related]
64. Novel triazines as potent and selective phosphodiesterase 10A inhibitors.
Malamas MS; Stange H; Schindler R; Lankau HJ; Grunwald C; Langen B; Egerland U; Hage T; Ni Y; Erdei J; Fan KY; Parris K; Marquis KL; Grauer S; Brennan J; Navarra R; Graf R; Harrison BL; Robichaud A; Kronbach T; Pangalos MN; Brandon NJ; Hoefgen N
Bioorg Med Chem Lett; 2012 Sep; 22(18):5876-84. PubMed ID: 22902656
[TBL] [Abstract][Full Text] [Related]
65. Evolution and synthesis of novel orally bioavailable inhibitors of PDE10A.
Burdi DF; Campbell JE; Wang J; Zhao S; Zhong H; Wei J; Campbell U; Shao L; Herman L; Koch P; Jones PG; Hewitt MC
Bioorg Med Chem Lett; 2015 May; 25(9):1864-8. PubMed ID: 25863433
[TBL] [Abstract][Full Text] [Related]
66. Discovery of MK-8189, a Highly Potent and Selective PDE10A Inhibitor for the Treatment of Schizophrenia.
Layton ME; Kern JC; Hartingh TJ; Shipe WD; Raheem I; Kandebo M; Hayes RP; Huszar S; Eddins D; Ma B; Fuerst J; Wollenberg GK; Li J; Fritzen J; McGaughey GB; Uslaner JM; Smith SM; Coleman PJ; Cox CD
J Med Chem; 2023 Jan; 66(2):1157-1171. PubMed ID: 36624931
[TBL] [Abstract][Full Text] [Related]
67. IRAK-4 inhibitors. Part II: a structure-based assessment of imidazo[1,2-a]pyridine binding.
Buckley GM; Ceska TA; Fraser JL; Gowers L; Groom CR; Higueruelo AP; Jenkins K; Mack SR; Morgan T; Parry DM; Pitt WR; Rausch O; Richard MD; Sabin V
Bioorg Med Chem Lett; 2008 Jun; 18(11):3291-5. PubMed ID: 18482836
[TBL] [Abstract][Full Text] [Related]
68. Inhibition mechanism exploration of quinoline derivatives as PDE10A inhibitors by in silico analysis.
Wu Q; Gao Q; Guo H; Li D; Wang J; Gao W; Han C; Li Y; Yang L
Mol Biosyst; 2013 Mar; 9(3):386-97. PubMed ID: 23354020
[TBL] [Abstract][Full Text] [Related]
69. The design and synthesis of indazole and pyrazolopyridine based glucokinase activators for the treatment of type 2 diabetes mellitus.
Pfefferkorn JA; Tu M; Filipski KJ; Guzman-Perez A; Bian J; Aspnes GE; Sammons MF; Song W; Li JC; Jones CS; Patel L; Rasmusson T; Zeng D; Karki K; Hamilton M; Hank R; Atkinson K; Litchfield J; Aiello R; Baker L; Barucci N; Bourassa P; Bourbonais F; D'Aquila T; Derksen DR; MacDougall M; Robertson A
Bioorg Med Chem Lett; 2012 Dec; 22(23):7100-5. PubMed ID: 23089526
[TBL] [Abstract][Full Text] [Related]
70. The rational search for PDE10A inhibitors from Sophora flavescens roots using pharmacophore‑ and docking‑based virtual screening.
Fan HT; Guo JF; Zhang YX; Gu YX; Ning ZQ; Qiao YJ; Wang X
Mol Med Rep; 2018 Jan; 17(1):388-393. PubMed ID: 29115449
[TBL] [Abstract][Full Text] [Related]
71. Synthesis and in vitro evaluation of new analogues as inhibitors for phosphodiesterase 10A.
Zhang Z; Lu X; Xu J; Rothfuss J; Mach RH; Tu Z
Eur J Med Chem; 2011 Sep; 46(9):3986-95. PubMed ID: 21705115
[TBL] [Abstract][Full Text] [Related]
72. The discovery of tetrahydropyridine analogs as hNav1.7 selective inhibitors for analgesia.
Wu W; Li Z; Yang G; Teng M; Qin J; Hu Z; Hou L; Shen L; Dong H; Zhang Y; Li J; Chen S; Tian J; Zhang J; Ye L
Bioorg Med Chem Lett; 2017 May; 27(10):2210-2215. PubMed ID: 28385504
[TBL] [Abstract][Full Text] [Related]
73. Design and optimization of purine derivatives as in vivo active PDE10A inhibitors.
Chen L; Chen D; Tang L; Ren J; Chen J; Zhen X; Liu YC; Zhang C; Luo H; Shen J; Xiong B
Bioorg Med Chem; 2017 Jul; 25(13):3315-3329. PubMed ID: 28462841
[TBL] [Abstract][Full Text] [Related]
74. Design, Synthesis, and Pharmacological Evaluation of 5,6-Disubstituted Pyridin-2(1H)-one Derivatives as Phosphodiesterase 10A (PDE10A) Antagonists.
Lingam VS; Dahale DH; Rathi VE; Shingote YB; Thakur RR; Mindhe AS; Kummari S; Khairatkar-Joshi N; Bajpai M; Shah DM; Sapalya RS; Gullapalli S; Gupta PK; Gudi GS; Jadhav SB; Pattem R; Thomas A
J Med Chem; 2015 Oct; 58(20):8292-308. PubMed ID: 26421921
[TBL] [Abstract][Full Text] [Related]
75. PDE10A inhibitors: an assessment of the current CNS drug discovery landscape.
Chappie T; Humphrey J; Menniti F; Schmidt C
Curr Opin Drug Discov Devel; 2009 Jul; 12(4):458-67. PubMed ID: 19562642
[TBL] [Abstract][Full Text] [Related]
76. Targeting PDE10A GAF Domain with Small Molecules: A Way for Allosteric Modulation with Anti-Inflammatory Effects.
García AM; Brea J; González-García A; Pérez C; Cadavid MI; Loza MI; Martinez A; Gil C
Molecules; 2017 Sep; 22(9):. PubMed ID: 28869560
[TBL] [Abstract][Full Text] [Related]
77. Synthesis and evaluation of aryliden- and hetarylidenfuranone derivatives of usnic acid as highly potent Tdp1 inhibitors.
Zakharova O; Luzina O; Zakharenko A; Sokolov D; Filimonov A; Dyrkheeva N; Chepanova A; Ilina E; Ilyina A; Klabenkova K; Chelobanov B; Stetsenko D; Zafar A; Eurtivong C; Reynisson J; Volcho K; Salakhutdinov N; Lavrik O
Bioorg Med Chem; 2018 Aug; 26(15):4470-4480. PubMed ID: 30076000
[TBL] [Abstract][Full Text] [Related]
78. Design, synthesis and biological evaluation of novel imidazopyridines as potential antidiabetic GSK3β inhibitors.
Lee SC; Kim HT; Park CH; Lee DY; Chang HJ; Park S; Cho JM; Ro S; Suh YG
Bioorg Med Chem Lett; 2012 Jul; 22(13):4221-4. PubMed ID: 22672803
[TBL] [Abstract][Full Text] [Related]
79. Discovery of natural product inhibitors of phosphodiesterase 10A as novel therapeutic drug for schizophrenia using a multistep virtual screening.
Al-Nema M; Gaurav A; Akowuah G
Comput Biol Chem; 2018 Dec; 77():52-63. PubMed ID: 30240986
[TBL] [Abstract][Full Text] [Related]
80. Phosphodiesterase 10 inhibitors: new disease modifying drugs for Parkinson's disease?
García AM; Redondo M; Martinez A; Gil C
Curr Med Chem; 2014 Apr; 21(10):1171-87. PubMed ID: 24372206
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
